Analysts Set Benitec Biopharma Limited (NASDAQ:BNTC) PT at $27.00

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $27.00.

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Monday, April 20th. Guggenheim downgraded shares of Benitec Biopharma from a “buy” rating to a “neutral” rating in a research report on Wednesday. Evercore assumed coverage on shares of Benitec Biopharma in a research report on Tuesday, May 12th. They set an “outperform” rating and a $25.00 price target for the company. Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, TD Cowen restated a “buy” rating on shares of Benitec Biopharma in a research report on Monday, March 9th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. raised its position in shares of Benitec Biopharma by 92.0% during the 4th quarter. Simplify Asset Management Inc. now owns 151,163 shares of the biotechnology company’s stock worth $2,036,000 after purchasing an additional 72,438 shares during the last quarter. Empery Asset Management LP acquired a new position in shares of Benitec Biopharma during the 4th quarter worth about $747,000. SG Americas Securities LLC acquired a new position in shares of Benitec Biopharma during the 4th quarter worth about $111,000. JPMorgan Chase & Co. acquired a new position in shares of Benitec Biopharma during the 2nd quarter worth about $80,000. Finally, Bank of America Corp DE raised its position in shares of Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,587 shares during the last quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $11.18 on Monday. The firm has a 50-day simple moving average of $11.72 and a two-hundred day simple moving average of $11.85. The company has a market cap of $384.03 million, a P/E ratio of -9.81 and a beta of 0.27. Benitec Biopharma has a fifty-two week low of $9.85 and a fifty-two week high of $17.10.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. Equities research analysts forecast that Benitec Biopharma will post -1.04 EPS for the current year.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.